Abstract: The present invention discloses novel polymer compositions comprising cellulose acrylamide, acrylamide and/or a fluorescent indicator species, and membranes made with these compositions. Optical pH sensors for monitoring the pH in a fluid sample, and methods for making such pH sensors are also disclosed. The pH sensors have reduced sensitivity to sample components that can interfere with pH measurements.

Abstract: Unsaturated nitrogenous compounds are used as electron donors in conjunction with catalytic polymerization of addition polymerizable monomers such as olefins, using supported Ziegler-Natta catalysts. The electron donors may be used in the preparation of catalyst systems, thus serving as “internal” electron donors, or they may be added during or just prior to polymerization, as an “external” electron donor.

Abstract: A sacrificial plastic mold having an electroplatable backing is provided. One embodiment consists of the infusion of a softened or molten thermoplastic through a porous metal substrate (sheet, screen, mesh or foam) and into the features of a micro-scale molding tool contacting the porous metal substrate. Upon demolding, the porous metal substrate will be embedded within the thermoplastic and will project a plastic structure with features determined by the mold tool. This plastic structure, in turn, provides a sacrificial plastic mold mechanically bonded to the porous metal substrate which provides a conducting support suitable for electroplating either contiguous or non-contiguous metal replicates. After electroplating and lapping, the sacrificial plastic can be dissolved to leave the desired metal structure bonded to the porous metal substrate. Optionally, the electroplated structures may be debonded from the porous substrate by selective dissolution of the porous substrate or a coating thereon.

Abstract: The present invention provides a method and device for the acoustic ejection of fluid droplets from fluid-containing reservoirs using focusing means having an F-number greater than approximately 2. The droplets are ejected toward designated sites on a substrate surface for deposition thereon. In one embodiment, the device is comprised of: a plurality of reservoirs each adapted to contain a fluid; an ejector comprising a means for generating acoustic radiation and a large F-numbered means for focusing the acoustic radiation at a focal point near the fluid surface in each of the reservoirs; and a means for positioning the ejector in acoustically coupled relationship to each of the reservoirs. The invention is useful in a number of contexts, particularly in the preparation of biomolecular arrays.

Abstract: A device and a method are provided for holding a stereotactic probe in position after the probe has been precisely positioned by stereotactic procedures, such as brain surgery. The device, a stereotactic probe holder, is adjustable, as it is capable of being positioned to contact and grip a probe at a position between a stereotactic frame and a patient's head, and is suitable for holding the probe in a desired location. Methods of using the stereotactic probe holder are also provided. The invention is useful in maintaining the proper positioning of probes, such as deep brain stimulators, electrodes, cryoprobes, cannulae, and the like, after the initial placement of the probes during stereotactic surgery.

Abstract: A method is provided for preventing or treating skin conditions, disorders or diseases, such as may be associated with or caused by inflammation, sun damage or natural aging. The method involves administration, preferably topical administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.

Abstract: A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as “as needed” basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.

Abstract: The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compositions by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compositions of the invention are particularly suitable for use in oral dosage forms.

Abstract: A liquid permeable metallic coating is utilized in conjunction with a fluorescence based optical sensor. The metallic coating is deposited directly on, and is in physical contact with, the sensing membrane. The metallic coating does not require an intervening substrate layer or other components. When light from a light source is shone through the substantially light transmissive substrate onto the sensing membrane, the metallic overcoating reflects back the excitation light as well as the fluorescence light generated by the sensor such that substantially no light reaches the sample where the light may be scattered and/or absorbed by the sample. Accordingly, the accuracy and repeatability of the sensor is improved while the cost and production times associated with manufacturing the sensor are minimized.

Abstract: A method is provided for synthesizing metallocene compounds useful as polymerization catalysts and the like. The method involves (a) preparation of an amino alcohol-derived ligand by reacting a silane reactant with an amino alcohol in the presence of base, followed by (b) metallation of the ligand so provided. The metallocenes may be provided in chiral form when the amino alcohol contains an asymmetric center, and are thus useful in catalyzing stereospecific polymerization and other stereospecific bond formation reactions.

Abstract: Methods, formulations and kits are described for resuscitating a patient suffering from cardiac arrest, for enhancing the efficacy of cardiopulmonary resuscitation, for treating post-resuscitation hypotension, and for reducing the incidence of ventricular arrhythmias and myocardial dysfunction in a patient following cardiopulmonary resuscitation. Prior methods and agents often cause inotropic or chronotropic effects, which can lead to undesirable post-resuscitation myocardial dysfunction. The invention comprises administering a therapeutically effective amount of an &agr;2-receptor agonist that does not cross the blood-brain barrier, such as &agr;-methylnorepinephrine, to enhance cardiopulmonary resuscitation.

Abstract: A method is provided for catalytically transforming a functional group within a first reactant by reaction with a second reactant in the presence of a nonmetallic, organic catalyst composition composed of a heteroatom-containing activator and an acid, or a salt of a heteroatom-containing activator and an acid. Exemplary first reactants are &agr;,&bgr;-unsaturated carbonyl compounds such as &agr;,&bgr;-unsaturated ketones and &agr;,&bgr;-unsaturated aldehydes. The heteroatom of the activator is a Group 15 or Group 16 element such as nitrogen, oxygen, sulfur or phosphorus, and exemplary heteroatom-containing activators are amines. Chiral heteroatom-containing activators can be used to catalyze enantioselective reactions, such that a chiral product is obtained from a chiral or achiral starting material in enantiomerically pure form.

Abstract: A novel Claisen rearrangement reaction is provided. An allylic reactant such as an allylic amine, an allylic ether or an allylic thioether is reacted with an acid chloride in the presence of a Lewis acid catalyst composition composed of a Lewis acid and a base selected from the group consisting of tertiary amines and non-nitrogenous bases. The stereochemistry of the reaction product is readily controlled by the positioning and size of substituents on the allylic reactant. The reaction may be carried out on a solid support, i.e., on the surface of a substrate suitable for conducting solid phase chemical reactions.

Abstract: Novel compounds are provided which are useful as catalysts, particularly in the polymerization of addition polymerizable monomers such as olefinic or vinyl monomers. The compounds are complexes of a mid-transition metal coordinated to at least two ligands, at least one of which is an unsaturated nitrogenous ligand. Depending on ligand substitution, stereospecific catalysts can be provided, including isospecific catalysts and syndiospecific catalysts. Catalyst systems containing the novel compounds in combination with a catalyst activator are provided as well, as are methods of using the novel compounds in the preparation of polyolefins.

Abstract: Novel pharmaceutical dosage forms provide for pulsatile delivery of methylphenidate, i.e., release encapsulated drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optionally third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads or particles, or may comprise a single tablet with the first, second and optionally third dosage units each representing an integral and discrete segment thereof. Methods of treatment using the pharmaceutical dosage forms are provided as well.

Abstract: Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.

Abstract: This invention relates generally to two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired. In particular, they are useful as tissue sealants, in promoting hemostasis, for drug delivery, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.

Abstract: The present invention relates to pharmaceutical compositions, pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. Compositions and systems of the present invention include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compositions and systems.

Abstract: Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.

Abstract: Stabilized bupropion hydrochloride pharmaceutical compositions are disclosed that are free of acid additives and provide for a sustained release of the bupropion hydrochloride. The particulate bupropion hydrochloride may be coated with a membrane coating and large-size particles may also be used. Methods for treating individuals using the stabilized bupropion hydrochloride pharmaceutical compositions are also provided.